JP2020504135A - 慢性閉塞性肺障害を処置するための方法および組成物 - Google Patents

慢性閉塞性肺障害を処置するための方法および組成物 Download PDF

Info

Publication number
JP2020504135A
JP2020504135A JP2019536859A JP2019536859A JP2020504135A JP 2020504135 A JP2020504135 A JP 2020504135A JP 2019536859 A JP2019536859 A JP 2019536859A JP 2019536859 A JP2019536859 A JP 2019536859A JP 2020504135 A JP2020504135 A JP 2020504135A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504135A5 (enExample
Inventor
ブラッドフォード アンドリュー ヤングブラッド，
ブラッドフォード アンドリュー ヤングブラッド，
ネナド トマセヴィック，
ネナド トマセヴィック，
クリストファー ロバート ベビントン，
クリストファー ロバート ベビントン，
Original Assignee
アラコス インコーポレイテッド
アラコス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス インコーポレイテッド, アラコス インコーポレイテッド filed Critical アラコス インコーポレイテッド
Publication of JP2020504135A publication Critical patent/JP2020504135A/ja
Publication of JP2020504135A5 publication Critical patent/JP2020504135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019536859A 2017-01-06 2018-01-05 慢性閉塞性肺障害を処置するための方法および組成物 Pending JP2020504135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443591P 2017-01-06 2017-01-06
US62/443,591 2017-01-06
PCT/US2018/012694 WO2018129400A1 (en) 2017-01-06 2018-01-05 Methods and compositions for treating chronic obstructive pulmonary disorder

Publications (2)

Publication Number Publication Date
JP2020504135A true JP2020504135A (ja) 2020-02-06
JP2020504135A5 JP2020504135A5 (enExample) 2021-02-12

Family

ID=62790958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536859A Pending JP2020504135A (ja) 2017-01-06 2018-01-05 慢性閉塞性肺障害を処置するための方法および組成物

Country Status (4)

Country Link
US (1) US20190338027A1 (enExample)
EP (1) EP3565597A4 (enExample)
JP (1) JP2020504135A (enExample)
WO (1) WO2018129400A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6825909B2 (ja) 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131155A1 (en) * 2014-02-28 2015-09-03 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4860877B2 (ja) * 2000-03-07 2012-01-25 ジョンズ・ホプキンス・ユニバーシティ シアロアドへジンファクター−２抗体
KR20210125114A (ko) * 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
HK1254432A1 (zh) * 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131155A1 (en) * 2014-02-28 2015-09-03 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PULMONARY PHARMACOLOGY ANDTHERAPEUTICS, vol. 24, JPN6021052018, 2011, pages 367 - 372, ISSN: 0004823453 *

Also Published As

Publication number Publication date
EP3565597A1 (en) 2019-11-13
US20190338027A1 (en) 2019-11-07
WO2018129400A1 (en) 2018-07-12
EP3565597A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
KR102311761B1 (ko) 항-Siglec-8 항체 및 그의 사용 방법
JP2023099232A (ja) 炎症性消化器障害を処置するための方法および組成物
JP2017501744A5 (enExample)
JP7034911B2 (ja) 全身性肥満細胞症を処置するための方法および組成物
JP2017507945A (ja) シグレック−８関連疾患を処置するための方法および組成物
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
CN113747918A (zh) 治疗肥大细胞胃炎、肥大细胞食管炎、肥大细胞肠炎、肥大细胞十二指肠炎和/或肥大细胞胃肠炎的方法和组合物
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
AU2022347172A1 (en) Anti-siglec-6 antibodies and methods of use thereof
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
KR20230093293A (ko) 항-siglec-8 항체 제형
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
WO2022061032A1 (en) Methods and compositions for treating viral infection
EP4048698A1 (en) Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220712